7 Best Stocks for the Next 30 Days

Get them in a free Special Report, and get more Zacks Insights in our free e-newsletter, Profit from the Pros. Every issue includes a fresh Zacks #1 Bull Stock of the Day.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 05/23/2013

Company Name Symbol %Change
WESTELL TECH WSTL
6.67%
STEIN MART I SMRT
5.38%
ALLIANCE FIB AFOP
5.21%
DAWSON GEOPH DWSN
4.33%
MARRIOTT VAC VAC
3.27%

Gentiva Health Services (GTIV)

by Zacks Equity Research

November 16, 2011 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Gentiva Health Services' (GTIV) third-quarter 2011 earnings lagged the Zacks Consensus Estimate, on the back of high interest payments as well as increasing operating expenses, thereby leading to a net loss and a negative operating cash flow. Reimbursement rate cuts and divestitures have led to reduced earnings guidance for 2011.

Ratings downgrade and legal trouble were the other downsides. Overall, the future outlook for Gentiva does not look very promising.

Our six-month target price of $5.00 equates to 3.0x our earnings estimate for 2011. This price target implies an expected total negative return of 7.9% over that period. This is consistent with our Underperform recommendation on the shares.

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.